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Thromboprophylaxis in COVID-19: Anti-FXa—the
Missing Factor?
To the Editor:
Coronavirus disease (COVID-19) infection was declared a public
health emergency of international concern in January 2020. The
medical literature has since seen a succession of reports questioning
a link between the disease in its severe form, a dynamic spectrum
of coagulopathy, and a concerning incidence of thrombotic
complications. As we accumulate observational data from around
the globe and await well-designed prospective studies to inform
best practice, clinical guidance on the management of thrombotic
risk remains pragmatic.
We have read with interest initial reports from Wuhan, China,
describing significant differences in D-dimer levels between
survivors and nonsurvivors of COVID-19 and the overt presence of
disseminated intravascular coagulation in over 70% of deaths (1). In
light of the histological features of thrombotic occlusion of the
pulmonary vasculature at autopsy (2), the Shanghai Clinical
Treatment Group advised the early application of anticoagulation
therapy in severe COVID-19. This led to a retrospective
comparison of patients who had not received any heparin before
the guidance with those who had, and, unsurprisingly, heparin
treatment was associated with a reduced mortality. A prophylactic
dose of low-molecular-weight heparin (LMWH) was mostly used;
however, the authors proposed that a higher dose may be more
beneficial for non-Asian patients (3).
With growing awareness of a distinct coagulopathy
accompanying COVID-19 infection, the medical community has
been keen to address the significant thrombotic risk for this patient
group. Institutions have anecdotally reported what were perceived to
be higher than expected rates of pulmonary embolus (PE), deep vein
thrombosis, and occlusion of citrated circuits.
Klok and colleagues reported a 31% cumulative incidence of
venous and arterial thrombosis, increasing to 49% after adjustment
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for competing risk of death, despite anticoagulant therapy in
patients admitted to the intensive therapy unit (ITU). The
authors suggested that ITU patients may warrant higher
thromboprophylaxis dosing such as enoxaparin 40 mg twice daily
versus 40 mg once daily (4).
Helms and colleagues compared a prospective cohort of ITU
patients with COVID-19 with a historical cohort non–COVID-19
acute respiratory distress syndrome (ARDS). They also observed a
high prevalence of clinically relevant thrombosis, most commonly
PE (16.7%), despite prophylactic or therapeutic anticoagulation;
this was usually diagnosed within a few days of ITU admission. The
authors advised that anticoagulant treatment should be guided by
anti–factor Xa (anti-FXa) activity and that higher targets would
likely be required (5).
Interestingly, Middeldorp and colleagues compared ITU
patients with ward patients and commented on a much lower rate of
venous thromboembolism (VTE) in the latter (6).
The consensus from reports to date is that there appears to
be a greater than expected VTE risk despite pharmacological
thromboprophylaxis. Authors consistently acknowledge the current
divergence in thromboprophylaxis dosing from what would usually
be considered a standard dose (Table 1).
We reviewed anti-FXa activity in patients admitted to hospital
with COVID-19 infection, all receiving pharmacological
thromboprophylaxis with enoxaparin 40 mg once daily, creatinine
clearance of .30 ml/min, and platelet count of .303 109/L (7).
We compared 4-hour after dose anti-FXa activity levels for 22 ward
patients and 20 ITU patients (Table 2).
With a significantly lower mean anti-FXa activity of 0.1
IU/ml, 95% of ITU patients failed to achieve a target anti-FXa
activity (0.2–0.4 IU/ml) compared with 27% ward patients.
This difference appeared to relate to the degree of respiratory
support required. Patients admitted with COVID-19 now
receive weight-adjusted LMWH thromboprophylaxis with anti-
FXa–guided dose escalation/reduction to achieve target
anticoagulation levels.
These preliminary data suggest that patients admitted to
ITU with COVID-19 may warrant a higher starting dose of
pharmacological thromboprophylaxis, an approach that has already
been adopted in some institutions. Furthermore, anti-FXa–guided
LMWH dosing may have a role in ward patients because almost
30% of these patients demonstrate suboptimal anti-FXa target
levels with standard dosing and merit early dose escalation.
LMWH is broadly used in hospital patients for the prevention
and treatment of VTE owing to a relatively predictable
pharmacokinetic profile and ease of monitoring. The anticoagulant
effect is measured using the anti-FXa activity. Monitoring for
prophylaxis is not routinely used; however, on the basis of studies
published, a reasonable target range for prophylaxis has been
suggested as between 0.2 and 0.4/0.5 IU/ml (8). There are
recognized situations, such as in pregnancy, renal impairment,
and obesity, in which standard doses may not achieve optimal
Table 1. Thromboprophylaxis Regimes from Studies Reporting the Incidence of VTE in Patients with COVID-19 Infection
Study Heparin Dose Patient Cohort
Tang and colleagues (4) Enoxaparin 40–60 mg once daily ITU
UFH 10–15,000 u once daily
Klok and colleagues (5) Nadroparin 2,850 IU once daily* increased in some to 5,700 IU
twice daily later in study†
ITU
Helms and colleagues (6) Not stated Prophylactic/therapeutic ITU
Middeldorp and colleagues (7) Nadroparin 2,850 IU once daily increased to twice daily later in
study*
ITU
Nadroparin 2,850 IU once daily Ward
Definition of abbreviations: COVID-19= coronavirus disease; ITU= intensive therapy unit; UFH=unfractionated heparin; VTE= venous thromboembolism.
*5,700 IU once daily for patients weighing more than 100 kg.
†For patients weighing more than 100 kg, the dose was increased to 5,700 IU twice daily.
Table 2. Comparison of Ward Patients and ITU Patients Receiving Standard-Dose LMWH Thromboprophylaxis
ITU (n=20) Ward (n= 22) Significance
Mean anti-FXa, IU/ml 0.10 0.25 P, 0.001*
Range (SD) 0.01–0.22 (0.06) 0.01–0.45 (0.12)
Number of patients with anti-FXa 0.2–0.4 IU/ml 1 16
Mean age, yr 50.6 61.1 P=0.049*
Range (SD) 26–66 (11.8) 21–91 (20.2)
Mean weight, kg 88.5 82.6 P=0.3*
Range (SD) 60–120 (14.9) 57–133 (20.6)
Respiratory support 19 intubated; 1 CPAP 22 wall-oxygen; max FIO2 0.35
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thromboprophylaxis. Uncertainty remains, however, regarding
the value of anti-FXa monitoring in such groups. The
consideration of patient-specific risk factors for thrombosis and
hemorrhage, together with the relationship between anti-FXa
activity and clinical outcome, may be more important (9). This is
of particular relevance in COVID-19, in which there is a
recognized spectrum of thrombosis and bleeding risk in later
stages of the infection (7). Furthermore, the growing autopsy
histology literature demonstrates a heterogeneity of thrombotic
disease manifestations, including mutually exclusive deep vein
thrombosis and PE, often despite anticoagulant therapy (10). For
pulmonary vascular occlusion that is more thrombotic than
embolic, higher LMWH doses may not necessarily be more
effective, and therefore the mechanism and relative contribution
of the thrombotic burden to death and the best anticoagulation
approach remain critical questions.
Potential mechanisms for the development of what appears to
be an acquired heparin resistance include reduced antithrombin
levels, as seen in patients with sepsis requiring ITU care. The
coagulopathy of COVID-19, however, appears to differ (1). As a
result of a disrupted equilibrium and the well-recognized battle
between inflammation and coagulation at the endothelial surface,
more heparin is required to counteract excess thrombin
generation in patients with severe disease (11). We also know that
significantly raised plasma concentrations of tissue factor and
PAI-1 (plasminogen activator inhibitor‐1) occur on
approximately day 7 in patients with ARDS, which could in turn
lead to increased alveolar fibrinolysis from an increase in local
PAI-1 (12). Taken in the clinical context, patients who require
higher levels of ventilation or develop ARDS may warrant
increased doses of LMWH thromboprophylaxis, resulting in
discordant anti-FXa activity. Interestingly, ARDS has also been
identified as a risk factor for VTE prophylaxis failure in critically
ill patients with sepsis (13).
Clinical thrombotic endpoints will undoubtedly form an
important component of upcoming randomized controlled
trials designed to define the relationship between optimal
anticoagulation and thrombosis outcomes in COVID-19. Until
then, the optimization of the anticoagulation strategy remains
paramount. Amid consistent concerns for more effective
prophylactic LMWH dosing, our data provide missing information
regarding anti-FXa activity, confirming lower than expected
activity, particularly in patients managed in the ITU. This
informs the move by many institutions to start with higher
thromboprophylaxis dosing pending the results of randomized
controlled trials and provides additional clues as to the nature of
the COVID-19–associated coagulopathy. n
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